-
07:29:15 PM

ANIP Stock News

03/09/23 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
ANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three and 12 months ended December 31, 2022. Net revenues were $94.2 million compared to $60.9 million in Q4 2021. GAAP net loss available to common shareholders was million, and diluted GAAP loss per share was. Adjusted non-GAAP EBITDA was $23.3 million compared to...
RHEA-AI
neutral
03/02/23 7:00 AM
Nasdaq : ANIP
low float
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
Cosette Pharmaceuticals, Inc. has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180 gm in an agreement with ANI Pharmaceuticals, Inc. and commenced shipping to customers this week. Apurva Saraf, President and CEO of Cosette Pharmaceuticals. Apurva Saraf, President and CEO of Cosette, stated "This launch is further evidence of Cosette’...
RHEA-AI
neutral
02/22/23 4:05 PM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results...
RHEA-AI
neutral
12/19/22 4:56 PM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Levocarnitine Tablets USP, 330 mg. The current annual U.S. market for Levocarnitine Tablets is approximately $10.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
RHEA-AI
neutral
11/28/22 6:50 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
ANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Fluoxetine Oral Solution, USP 20 mg/5 mL. The current annual U.S. market for Fluoxetine Oral Solution is approximately $14.6 million, according to IQVIA/IMS Health, a leading healthcare data and...
RHEA-AI
neutral
11/16/22 6:50 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Trimethoprim Tablets USP, 100 mg. The current annual U.S. market for Trimethoprim Tablets is approximately $16.8 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
RHEA-AI
very positive
11/09/22 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
ANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three and nine months ended September 30, 2022. We are pleased to share that ANI delivered record net revenues of $83.8 million and significant sequential gains of non-GAAP EBITDA, which at $19.6 million is nearly double that of the second quarter of 2022.
RHEA-AI
neutral
10/24/22 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, prior to market open. ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription...
RHEA-AI
neutral
08/30/22 4:05 PM
Nasdaq : ANIP
conferenceslow float
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription...
RHEA-AI
neutral